15350 Sherman Way
86 articles about HemaCare Corp.
Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
12/16/2019Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
Advancing cell and gene therapies with the highest quality GMP-compliant bone marrow starting material
HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples
Advancing discoveries by providing scientists with high-quality disease-state biospecimens to support preclinical and clinical research
HemaCare Corporation announced operational highlights and financial results for the year ended December 31, 2018.
HemaCare’s Global Head of Cell Therapy speaking at 1:30 pm EST on January 23, 2019
HemaCare Corporation today announced the company has moved its global headquarters to Northridge, California.
HemaCare Corp. (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces their involvement as a provider of leukapheresis process development material for 100% of the current FDA-approved immunocellular therapies, Kymriah® (Novartis; Switzerland), Yescarta® (Kite, a Gilead Company; CA, USA), and Provenge® (Dendreon; WA, USA).
HemaCare Corporation announced operational highlights and financial results for the six months ended June 30, 2018.
HemaCare Expands Development of Cellular Therapy Services by Bolstering Scientific Team with Two Strategic New Hires
Industry mavens strengthen HemaCare’s expertise in cell therapy and bioprocessing
HemaCare Corporation announced operational highlights and financial results for the year ended December 31, 2017.
HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development
HemaCare and Charles River Laboratories have formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.
Under the terms of the agreement signed January 6, 2017, OneBlood is purchasing an additional 363,786 shares at $3.44 per share.